Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

BRISTOL, Va. (WDBJ) - Fire crews were called back to the former Virginia Intermont College campus in Bristol this past ...

This was the stock's second consecutive day of losses.

All traffic has been stopped on the M5 after a crash near Bristol this evening (Monday, December 30). The collision took ...

We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take ...

Bristol logistics tech company Huboo has been saved from administration and bought by an investor consortium, the firm has ...

The financial accounts of Bristol City's parent company, Bristol City Holdings Limited, for the year ended June 2024 show a pre-tax loss of £3.3m. The figures are a major improvement, however, on the ...

Freddie Potts and George Earthy faced off in the EFL Championship as Earthy’s Bristol City defeated Potts’ Portsmouth 3-0.

IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

Bristol has been named in the top ten venues for a stag do in Europe - and is now above Amsterdam and Krakow. And according ...